Previous 10 | Next 10 |
2024-01-04 18:28:07 ET More on Kymera Therapeutics Kymera Therapeutics Merits Cautious 'Wait-And-See' Approach For Inflammatory Skin Diseases Kymera Therapeutics, Inc. (KYMR) Q3 2023 Earnings Call Transcript Kymera stock dips 5% following BofA downgrade Seeki...
2024-01-04 16:04:23 ET More on Kymera Therapeutics Kymera Therapeutics Merits Cautious 'Wait-And-See' Approach For Inflammatory Skin Diseases Seeking Alpha’s Quant Rating on Kymera Therapeutics Historical earnings data for Kymera Therapeutics For furth...
WATERTOWN, Mass., Jan. 04, 2024 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using targeted protein degradation (TPD), today announced that it has commenced an underwritten public off...
Company’s focus on advancing first-in-class oral degraders with biologics-like activity to address areas of significant patient need and market potential STAT6 oral degrader KT-621, with dupilumab-like activity, expected to enter Phase 1 clinical trial in the second half of 2024 ...
2024-01-03 12:58:20 ET More on Kymera Therapeutics Kymera Therapeutics Merits Cautious 'Wait-And-See' Approach For Inflammatory Skin Diseases Kymera Therapeutics, Inc. (KYMR) Q3 2023 Earnings Call Transcript Seeking Alpha’s Quant Rating on Kymera Therapeutics ...
WATERTOWN, Mass., Jan. 02, 2024 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using targeted protein degradation (TPD), today announced the Company will present at the 42 nd Annual...
2023-12-29 15:00:18 ET More on the markets Sentiment Speaks: The Fed Is Going To Put A Big Hurt On Everyone In 2024 5 Big Market Predictions For 2024 2024 Analyst Outlook: Lawrence Fuller On An Economic Soft Landing Scenario A Peak In Excess Liquidity May Mea...
2023-12-16 19:30:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
WATERTOWN, Mass., Dec. 13, 2023 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using targeted protein degradation (TPD), today shared webcast information for the virtual Immunology R&am...
STAT3 Degrader KT-333 showed early signs of antitumor activity across liquid and solid tumors, including major responses in cutaneous T-cell lymphoma (CTCL) and Hodgkin’s lymphoma Robust STAT3 knockdown and positive immunomodulatory effect demonstrated in tumor as well as blood...
News, Short Squeeze, Breakout and More Instantly...
Kymera Therapeutics Inc. Company Name:
KYMR Stock Symbol:
NASDAQ Market:
Abstract released today highlights safety, pharmacodynamic and clinical response data collected through February 6, 2024 cut-off date Updated data...
Abstract released today highlights safety, pharmacodynamic and clinical response data collected through February 6, 2024 cut-off date Updated data to be presented at the European Hematology Association (EHA) Annual Meeting KT-333 Phase 1 study ongoing with additional data expect...
2024-05-12 08:48:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...